{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:16:31Z","timestamp":1761581791319,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00066-019-01429-6","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:12:10Z","timestamp":1548893530000},"page":"872-881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate","Ergebnisse der lokoregionalen Strahlentherapie bei metastatischen kastrationsresistenten und mit Abirateronacetat behandelten Prostakarzinompatienten"],"prefix":"10.1007","volume":"195","author":[{"given":"Berna Akkus","family":"Yildirim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-9021","authenticated-orcid":false,"given":"Cem","family":"Onal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Kose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezgi","family":"Oymak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Murat","family":"Sedef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Ayberk","family":"Besen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozan Cem","family":"Guler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Taner","family":"Sumbul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sad\u0131k","family":"Muallaoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huseyin","family":"Mertsoylu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokhan","family":"Ozyigit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"issue":"1","key":"1429_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67(1):7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21387","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"1429_CR2","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.juro.2015.06.106","volume":"194","author":"ED Crawford","year":"2015","unstructured":"Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP (2015) Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J\u00a0Urol 194(6):1537\u20131547. \n                    https:\/\/doi.org\/10.1016\/j.juro.2015.06.106","journal-title":"J Urol"},{"issue":"21","key":"1429_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono de","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. N\u00a0Engl J Med 364(21):1995\u20132005. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"issue":"13","key":"1429_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N\u00a0Engl J Med 367(13):1187\u20131197. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"issue":"9747","key":"1429_CR5","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS Bono de","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a\u00a0randomised open-label trial. Lancet 376(9747):1147\u20131154. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(10)61389-X","journal-title":"Lancet"},{"issue":"5","key":"1429_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N\u00a0Engl J Med 363(5):411\u2013422. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1001294","journal-title":"N Engl J Med"},{"issue":"3","key":"1429_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall\u2019Oglio M, Franzen L, Coleman R, Vogelzang NJ, O\u2019Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, ALSYMPCA Investigators (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N\u00a0Engl J Med 369(3):213\u2013223. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1213755","journal-title":"N Engl J Med"},{"issue":"5","key":"1429_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, PREVAIL Investigators (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N\u00a0Engl J Med 371(5):424\u2013433. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1405095","journal-title":"N Engl J Med"},{"issue":"4","key":"1429_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045","volume":"1","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a\u00a0randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 1(4):152\u2013160. \n                    https:\/\/doi.org\/10.1016\/S1470-2045","journal-title":"Lancet Oncol"},{"issue":"23","key":"1429_CR10","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1200\/JCO.2007.15.9517","volume":"26","author":"SM Dy","year":"2008","unstructured":"Dy SM, Asch SM, Naeim A, Sanati H, Walling A, Lorenz KA (2008) Evidence-based standards for cancer pain management. J\u00a0Clin Oncol 26(23):3879\u20133885. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.15.9517","journal-title":"J Clin Oncol"},{"issue":"9286","key":"1429_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","volume":"358","author":"GH Mickisch","year":"2001","unstructured":"Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a\u00a0randomised trial. Lancet 358(9286):966\u2013970","journal-title":"Lancet"},{"issue":"17","key":"1429_CR12","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1200\/JCO.2004.10.218","volume":"22","author":"LK Temple","year":"2004","unstructured":"Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D (2004) Use of surgery among elderly patients with stage IV colorectal cancer. J\u00a0Clin Oncol 22(17):3475\u20133484. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.10.218","journal-title":"J Clin Oncol"},{"issue":"7","key":"1429_CR13","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/cncr.25467","volume":"117","author":"ZA Alicikus","year":"2011","unstructured":"Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, Cox B, Zelefsky MJ (2011) Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 117(7):1429\u20131437. \n                    https:\/\/doi.org\/10.1002\/cncr.25467","journal-title":"Cancer"},{"issue":"5","key":"1429_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.urolonc.2013.12.003","volume":"32","author":"SH Culp","year":"2014","unstructured":"Culp SH, Karam JA, Wood CG (2014) Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urol Oncol 32(5):561\u2013568. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2013.12.003","journal-title":"Urol Oncol"},{"issue":"1","key":"1429_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2014.08.056","volume":"67","author":"N Fossati","year":"2015","unstructured":"Fossati N, Trinh QD, Sammon J, Sood A, Larcher A, Sun M, Karakiewicz P, Guazzoni G, Montorsi F, Briganti A, Menon M, Abdollah F (2015) Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a\u00a0SEER-based study. Eur Urol 67(1):3\u20136. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2014.08.056","journal-title":"Eur Urol"},{"issue":"2","key":"1429_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.juro.2015.02.084","volume":"194","author":"R Satkunasivam","year":"2015","unstructured":"Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, Lewinger JP, Stern MC, Hamilton AS, Aron M, Gill IS (2015) Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J\u00a0Urol 194(2):378\u2013385. \n                    https:\/\/doi.org\/10.1016\/j.juro.2015.02.084","journal-title":"J Urol"},{"issue":"7","key":"1429_CR17","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J\u00a0Clin Oncol 26(7):1148\u20131159. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.12.4487","journal-title":"J Clin Oncol"},{"key":"1429_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-018-1265-8","author":"R Aizawa","year":"2018","unstructured":"Aizawa R, Takayama K, Nakamura K, Inoue T, Kobayashi T, Akamatsu S, Yamasaki T, Ogawa O, Mizowaki T (2018) Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer. Int J Clin Oncol. \n                    https:\/\/doi.org\/10.1007\/s10147-018-1265-8","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"1429_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/0360-3016(95)02005-0","volume":"33","author":"SP Lankford","year":"1995","unstructured":"Lankford SP, Pollack A, Zagars GK (1995) Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys 33(4):907\u2013912. \n                    https:\/\/doi.org\/10.1016\/0360-3016(95)02005-0","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"1429_CR20","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00432-013-1520-3","volume":"139","author":"A Botticella","year":"2013","unstructured":"Botticella A, Guarneri A, Filippi AR, Levra NG, Munoz F, Ragona R, Gontero P, Ricardi U (2013) May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy? J\u00a0Cancer Res Clin Oncol 139(11):1955\u20131960. \n                    https:\/\/doi.org\/10.1007\/s00432-013-1520-3","journal-title":"J Cancer Res Clin Oncol"},{"issue":"15","key":"1429_CR21","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N\u00a0Engl J Med 351(15):1502\u20131512. \n                    https:\/\/doi.org\/10.1056\/NEJMoa040720","journal-title":"N Engl J Med"},{"issue":"8","key":"1429_CR22","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(08)70201-8","volume":"9","author":"IJ Fidler","year":"2008","unstructured":"Fidler IJ, Poste G (2008) The \u201cseed and soil\u201d hypothesis revisited. Lancet Oncol 9(8):808. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(08)70201-8","journal-title":"Lancet Oncol"},{"issue":"23","key":"1429_CR23","doi-asserted-by":"publisher","first-page":"11089","DOI":"10.1158\/0008-5472.CAN-06-2407","volume":"66","author":"RN Kaplan","year":"2006","unstructured":"Kaplan RN, Rafii S, Lyden D (2006) Preparing the \u201csoil\u201d: the premetastatic niche. Cancer Res 66(23):11089\u201311093. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2407","journal-title":"Cancer Res"},{"issue":"7","key":"1429_CR24","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","volume":"139","author":"MY Kim","year":"2009","unstructured":"Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massague J (2009) Tumor self-seeding by circulating cancer cells. Cell 139(7):1315\u20131326. \n                    https:\/\/doi.org\/10.1016\/j.cell.2009.11.025","journal-title":"Cell"},{"issue":"6","key":"1429_CR25","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.urology.2012.09.001","volume":"80","author":"L Resel Folkersma","year":"2012","unstructured":"Resel Folkersma L, San Jose Manso L, Galante Romo I, Moreno Sierra J, Olivier Gomez C (2012) Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology 80(6):1328\u20131332. \n                    https:\/\/doi.org\/10.1016\/j.urology.2012.09.001","journal-title":"Urology"},{"issue":"23","key":"1429_CR26","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMoa003013","volume":"345","author":"RC Flanigan","year":"2001","unstructured":"Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr., Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N\u00a0Engl J Med 345(23):1655\u20131659. \n                    https:\/\/doi.org\/10.1056\/NEJMoa003013","journal-title":"N Engl J Med"},{"issue":"24","key":"1429_CR27","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/jco.2016.67.4788","volume":"34","author":"CG Rusthoven","year":"2016","unstructured":"Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ (2016) Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J\u00a0Clin Oncol 34(24):2835\u20132842. \n                    https:\/\/doi.org\/10.1200\/jco.2016.67.4788","journal-title":"J Clin Oncol"},{"issue":"11","key":"1429_CR28","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED (2011) Characterising the castration-resistant prostate cancer population: a\u00a0systematic review. Int J Clin Pract 65(11):1180\u20131192. \n                    https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02799.x","journal-title":"Int J Clin Pract"},{"issue":"2","key":"1429_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N\u00a0Engl J Med 368(2):138\u2013148. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1209096","journal-title":"N Engl J Med"},{"issue":"12","key":"1429_CR30","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","volume":"90","author":"A O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M (2004) Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90(12):2317\u20132325. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6601879","journal-title":"Br J Cancer"},{"issue":"2","key":"1429_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.beem.2008.01.008","volume":"22","author":"V Luu-The","year":"2008","unstructured":"Luu-The V, Belanger A, Labrie F (2008) Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 22(2):207\u2013221. \n                    https:\/\/doi.org\/10.1016\/j.beem.2008.01.008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"16","key":"1429_CR32","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-16-2245","volume":"23","author":"EA Mostaghel","year":"2017","unstructured":"Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB (2017) Association of tissue Abiraterone levels and SLCO genotype with Intraprostatic steroids and pathologic response in men with high-risk localized prostate cancer. Clin Cancer Res 23(16):4592\u20134601. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2245","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1429_CR33","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.eururo.2016.02.055","volume":"70","author":"P Rescigno","year":"2016","unstructured":"Rescigno P, Lorente D, Bianchini D, Ferraldeschi R, Kolinsky MP, Sideris S, Zafeiriou Z, Sumanasuriya S, Smith AD, Mehra N, Jayaram A, Perez-Lopez R, Mateo J, Parker C, Dearnaley DP, Tunariu N, Reid A, Attard G, de Bono JS (2016) Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer. Eur Urol 70(5):724\u2013731. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.02.055","journal-title":"Eur Urol"},{"issue":"12","key":"1429_CR34","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1200\/JCO.1995.13.12.2944","volume":"13","author":"R Sridhara","year":"1995","unstructured":"Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ (1995) Evaluation of prostate-specific antigen as a\u00a0surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J\u00a0Clin Oncol 13(12):2944\u20132953. \n                    https:\/\/doi.org\/10.1200\/JCO.1995.13.12.2944","journal-title":"J Clin Oncol"},{"issue":"4","key":"1429_CR35","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1200\/JCO.1993.11.4.607","volume":"11","author":"WK Kelly","year":"1993","unstructured":"Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD (1993) Prostate-specific antigen as a\u00a0measure of disease outcome in metastatic hormone-refractory prostate cancer. J\u00a0Clin Oncol 11(4):607\u2013615. \n                    https:\/\/doi.org\/10.1200\/JCO.1993.11.4.607","journal-title":"J Clin Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-019-01429-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-019-01429-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-019-01429-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T19:03:30Z","timestamp":1580324610000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-019-01429-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1007\/s00066-019-01429-6","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"27 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.A.\u00a0Yildirim, C.\u00a0Onal, F.\u00a0Kose, E.\u00a0Oymak, A.M.\u00a0Sedef, A.A.\u00a0Besen, S.\u00a0Aksoy, O.C.\u00a0Guler, A.T.\u00a0Sumbul, S.\u00a0Muallaoglu, H.\u00a0Mertsoylu, and G.\u00a0Ozyigit declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}